DNA probes-based diagnostics is an emerging application area in the in-vitro diagnostics industry. DNA probes, popular across the medical diagnostics industry, determine the presence of a suspected disease caused by an organism or pathogen. Based on the amount of target DNA present, probes can be used either directly to detect target DNA, or indirectly target DNA through amplification that creates a number of copies of specific nucleotide. Increased automation of diagnostic tests, discovery of new diagnostic markets, rising investments in pharmaceutical and pharmacogenomics research, and advancements in DNA array technologies are major growth facilitators for the DNA probes-based diagnostic products market.
In the area of molecular in-vitro diagnostics, DNA based diagnostics represent the most attractive, and fast growing clinical diagnostics technology primarily due to high levels of reliability, sensitivity, and rapidity. Numerous technology breakthroughs in the area of DNA diagnostics include PCR-based techniques, DNA microarrays and microfluidics, fluorescent in situ hybridization (FISH), SNP detection, and DNA nanotechnology, among several others. Breaking from the realm of research, current applications of DNA diagnostics are becoming widespread, with millions of samples from blood, hair and tissues, being analyzed worldwide for the positive identification of pathogens and diseases. DNA diagnostic technologies are expected to incorporate superior efficiencies and improved activity across several application areas including healthcare, biomedical research, toxicology, bioremediation, forensics, environmental monitoring, biomass operations, industrial processing, and quality control in the food industry.
United States and Europe collectively hold more than 80% of the global DNA Probes-Based Diagnostics market for 2008, as stated in a recent report published by Global Industry Analysts, Inc. About 90% of DNA tests are performed in developed regions of North America, Western Europe and Japan. Advanced pockets in emerging nations in Asia are expected to witness strong potential. In the United States, infectious disease diagnosis represents the leading application area, with share exceeding 58% for the year 2008. Diagnostic tests for cancer holds immense growth opportunities in the industry.
France, Germany, and the United Kingdom capture over 50% share of the European market. In Europe, the market for DNA probes-based diagnostics for cancer is projected to cross US$774 million by 2012.
Key players profiled in the study include Abbott Laboratories, Affymetrix Inc, Becton Dickinson & Company, Beckman Coulter, bioMérieux, Biogenex Laboratories Inc., Celera Group, Gen-Probe Incorporated, Genzyme Corporation, Luminex Molecular Diagnostics, MP Biomedicals, Roche Diagnostics, Siemens Healthcare Diagnostics Inc., and QIAGEN.
The report titled "DNA Probes-Based Diagnostics: A Global Strategic Business Report" published by Global Industry Analysts, Inc., covers major market dynamics, trends, issues, and competition pertaining to the market. The report enumerates recent product introductions/innovations, developments, mergers, acquisitions and other strategic industry activities. Analysis is presented for established and emerging markets including United States, Japan, France, Germany, United Kingdom, Italy, Asia-Pacific, and Latin America for the period 2000-2015. The study analyzes the market by application area, namely Infectious Disease, Cancer, Genetic Predisposition, Identity/Forensics, Molecular HLA Testing, and Other Types of Diagnosis.
For more details of this research report, please visit http://www.strategyr.com/DNA_Probes_Based_Diagnostics_Market_Report.asp